



Contact: Jordan Curnes, COO
 Tel: 214.770.0935
 E-mail: jordan@microtransponder.com
 Website: www.Microtransponder.com

Funding:

- Texas Emerging Tech Fund (4/08)
 - **\$1,380,000**
- Venture Capital match (4/08)
 - **\$500,000**
- Phase I STTR NINDS (4/08)
 - **\$100,000**
- Texas ARP (4/08)
 - **\$150,000**
- Seeking Series A Funding (Q1 '09)

Use of Proceeds:

- GMP prototype
- Additional IP filings
- Animal data collection
- Clinical pilot trial

Competitive Advantage:

- Device
 - 100x smaller
 - Non-invasive, biocompatible
 - Injectable via needle
 - No migration inside the body
- Wireless & Programmable
 - Able to adapt to patient needs
 - No batteries inside the body

Business Model:

- Strategic partnership, licensing
- Supplement venture funding with grants

Management Team:

President and CEO	Will Rosellini JD MBA
Chief Medical Officer	Richard Weiner, MD
Chief Scientific Officer	Larry Cauller, PhD
Chief Operating Officer	Jordan Curnes, MBA
General Counsel	Frank McEachern, JD
VP of Development	Evelyn Hu, MS
VP of Grants	Reema Casavant, PhD

Elevator Pitch

- Large unmet need for \$20B chronic pain market
- Growing target population (Baby Boomers)
- Device is tiny, injectable, wireless, efficacious
- Top Neuroscience team at UTD conducting research
- Use existing reimbursement codes, attractive for acquisition or licensing opportunity

Business Plan

- Scientifically validated via NIH grant awards
- Strong IP portfolio, continue to file patent applications
- FDA label “Treatment for chronic pain of the trunk and limbs” through a FDA 510k clearance
- Continue accumulating data for follow-on neurological indications
- License or acquisition device companies

Problem

50M Americans suffer from chronic pain and go to 250M doctor visits.

- Current pharmaceuticals ineffective, major side effects (addiction/cognitive impairment)
- Current stimulators are invasive, prone to migrate or fail

Solution

We have invented a wireless medical device that is 100 times smaller than its nearest competitor. It is the size of a grain of sand, injectable via hypodermic needle, uses RFID technology, and is completely biocompatible. These devices block pain signals from reaching the brain.

Market Opportunity

- \$20B chronic pain market, 20% refractory patients
- \$1.7B Neurostimulation market will double in 5 years

Revenue Model

Seek FDA 510k clearance for chronic pain, license chronic pain indication to a medical device firm. Use capital to develop technology for additional neurological indications.

Company Highlights

- Dynamic, disruptive technology
- Large and growing market
- Scientific validation through NIH grants
- Strong IP portfolio with continuing development
- Partnership discussions underway with key companies
- Multiple exit strategies